{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T23:50:06Z","timestamp":1774914606930,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006676","name":"Lilly Deutschland","doi-asserted-by":"publisher","award":["project no. I1F-OE-O001"],"award-info":[{"award-number":["project no. I1F-OE-O001"]}],"id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s13555-024-01112-4","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T13:02:14Z","timestamp":1709902934000},"page":"613-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNF\u03b1"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-3626","authenticated-orcid":false,"given":"Julia","family":"Tittes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5191-9031","authenticated-orcid":false,"given":"Jennifer","family":"Brell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-5763","authenticated-orcid":false,"given":"Pia","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-436X","authenticated-orcid":false,"given":"Constanze","family":"Jonak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-4250","authenticated-orcid":false,"given":"Georg","family":"Stary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0878","authenticated-orcid":false,"given":"Julia M.","family":"Ressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-7483","authenticated-orcid":false,"given":"Sarojinidevi","family":"K\u00fcnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-8699","authenticated-orcid":false,"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-6975","authenticated-orcid":false,"given":"Johannes","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"issue":"3 Pt 1","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"1112_CR2","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735\u201341.","journal-title":"JAMA"},{"issue":"4","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1112_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nm0595-442","volume":"1","author":"SL Gottlieb","year":"1995","unstructured":"Gottlieb SL, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442\u20137.","journal-title":"Nat Med"},{"issue":"3","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"52","key":"1112_CR6","doi-asserted-by":"publisher","first-page":"19057","DOI":"10.1073\/pnas.0509736102","volume":"102","author":"MA Lowes","year":"2005","unstructured":"Lowes MA, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A. 2005;102(52):19057\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123\u201332.","journal-title":"Nat Immunol"},{"issue":"11","key":"1112_CR9","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ni1261","volume":"6","author":"H Park","year":"2005","unstructured":"Park H, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133\u201341.","journal-title":"Nat Immunol"},{"issue":"4","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1046\/j.1523-1747.1998.00347.x","volume":"111","author":"MB Teunissen","year":"1998","unstructured":"Teunissen MB, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111(4):645\u20139.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger JG, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"E Lee","year":"2004","unstructured":"Lee E, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125\u201330.","journal-title":"J Exp Med"},{"issue":"1","key":"1112_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/jid.2008.194","volume":"129","author":"LC Zaba","year":"2009","unstructured":"Zaba LC, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1\/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129(1):79\u201388.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1112_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4049\/jimmunol.1100123","volume":"187","author":"AM Lin","year":"2011","unstructured":"Lin AM, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490\u2013500.","journal-title":"J Immunol"},{"issue":"11","key":"1112_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/exd.12487","volume":"23","author":"RR Keijsers","year":"2014","unstructured":"Keijsers RR, et al. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799\u2013803.","journal-title":"Exp Dermatol"},{"issue":"7","key":"1112_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/exd.12710","volume":"24","author":"K Reich","year":"2015","unstructured":"Reich K, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529\u201335.","journal-title":"Exp Dermatol"},{"issue":"11","key":"1112_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014108","volume":"5","author":"PC Res","year":"2010","unstructured":"Res PC, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE. 2010;5(11): e14108.","journal-title":"PLoS ONE"},{"issue":"11","key":"1112_CR18","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1073\/pnas.83.11.3949","volume":"83","author":"K Haranaka","year":"1986","unstructured":"Haranaka K, et al. Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci U S A. 1986;83(11):3949\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1112_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","volume":"13","author":"AJ Schottelius","year":"2004","unstructured":"Schottelius AJ, et al. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13(4):193\u2013222.","journal-title":"Exp Dermatol"},{"issue":"26","key":"1112_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","volume":"334","author":"F Bazzoni","year":"1996","unstructured":"Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717\u201325.","journal-title":"N Engl J Med"},{"issue":"1","key":"1112_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20050500","volume":"202","author":"FO Nestle","year":"2005","unstructured":"Nestle FO, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202(1):135\u201343.","journal-title":"J Exp Med"},{"issue":"5","key":"1112_CR22","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1523-1747.ep12371679","volume":"101","author":"K Uyemura","year":"1993","unstructured":"Uyemura K, et al. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701\u20135.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1112_CR23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/bjd.12236","volume":"168","author":"RR Keijsers","year":"2013","unstructured":"Keijsers RR, et al. Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin. Br J Dermatol. 2013;168(6):1294\u2013302.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1112_CR24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, et al. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1112_CR25","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","volume":"7","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8707.","journal-title":"Sci Rep"},{"issue":"3","key":"1112_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"F Kolbinger","year":"2017","unstructured":"Kolbinger F, et al. \u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2017;139(3):923-932.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1112_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjd.14034","volume":"174","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136\u201345.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1112_CR28","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1038\/jid.2014.268","volume":"134","author":"CQF Wang","year":"2014","unstructured":"Wang CQF, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134(12):2990\u20133.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1112_CR29","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jid.2015.12.036","volume":"136","author":"DC Soler","year":"2016","unstructured":"Soler DC, et al. Increased, but functionally impaired, CD14(+) HLA-DR(-\/low) myeloid-derived suppressor cells in psoriasis: a mechanism of dysregulated T cells. J Invest Dermatol. 2016;136(4):798\u2013808.","journal-title":"J Invest Dermatol"},{"issue":"70","key":"1112_CR30","doi-asserted-by":"publisher","first-page":"eabm9409","DOI":"10.1126\/sciimmunol.abm9409","volume":"7","author":"E Kvedaraite","year":"2022","unstructured":"Kvedaraite E, Ginhoux F. Human dendritic cells in cancer. Sci Immunol. 2022;7(70):eabm9409.","journal-title":"Sci Immunol"},{"key":"1112_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929000","volume":"13","author":"N Scheib","year":"2022","unstructured":"Scheib N, et al. The dendritic cell dilemma in the skin: between tolerance and immunity. Front Immunol. 2022;13: 929000.","journal-title":"Front Immunol"},{"key":"1112_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941071","volume":"13","author":"M Kamata","year":"2022","unstructured":"Kamata M, Tada Y. Dendritic cells and macrophages in the pathogenesis of psoriasis. Front Immunol. 2022;13: 941071.","journal-title":"Front Immunol"},{"key":"1112_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo M, et al. Dendritic cells revisited. Annu Rev Immunol. 2021;39:131\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1112_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1080\/09546634.2021.1899112","volume":"33","author":"A Narcisi","year":"2022","unstructured":"Narcisi A, et al. Effects of TNF-\u03b1 inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. J Dermatol Treat. 2022;33(3):1703\u20136.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"1112_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","volume":"59","author":"T Simopoulou","year":"2023","unstructured":"Simopoulou T, et al. Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs Today (Barc). 2023;59(3):135\u201367.","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"1112_CR37","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","volume":"40","author":"C Lynde","year":"2023","unstructured":"Lynde C, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869\u201386.","journal-title":"Adv Ther"},{"issue":"10","key":"1112_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.15252\/emmm.201404114","volume":"6","author":"E Glitzner","year":"2014","unstructured":"Glitzner E, et al. Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med. 2014;6(10):1312\u201327.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1112_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/ijms19010042","volume":"19","author":"TG Kim","year":"2017","unstructured":"Kim TG, Kim SH, Lee MG. The origin of skin dendritic cell network and its role in psoriasis. Int J Mol Sci. 2017;19(1):42.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1112_CR40","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba LC, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183\u201394.","journal-title":"J Exp Med"},{"issue":"6","key":"1112_CR41","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1073\/pnas.0409569102","volume":"102","author":"F Chamian","year":"2005","unstructured":"Chamian F, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102(6):2075\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1112_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/1346-8138.15184","volume":"47","author":"A Wang","year":"2020","unstructured":"Wang A, Bai Y. Dendritic cells: the driver of psoriasis. J Dermatol. 2020;47(2):104\u201313.","journal-title":"J Dermatol"},{"issue":"5","key":"1112_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20031482","volume":"199","author":"O Boyman","year":"2004","unstructured":"Boyman O, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004;199(5):731\u20136.","journal-title":"J Exp Med"},{"issue":"7162","key":"1112_CR44","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature06116","volume":"449","author":"R Lande","year":"2007","unstructured":"Lande R, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564\u20139.","journal-title":"Nature"},{"issue":"5","key":"1112_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1365-2133.2008.08508.x","volume":"158","author":"A Farkas","year":"2008","unstructured":"Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol. 2008;158(5):921\u20139.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1112_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00262-012-1294-5","volume":"61","author":"CA Dumitru","year":"2012","unstructured":"Dumitru CA, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155\u201367.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1112_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319.","journal-title":"Nat Immunol"},{"key":"1112_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2020.00109","volume":"10","author":"C Bergenfelz","year":"2020","unstructured":"Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 2020;10:109.","journal-title":"Front Oncol"},{"issue":"12","key":"1112_CR49","first-page":"4756","volume":"61","author":"J Schmielau","year":"2001","unstructured":"Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756\u201360.","journal-title":"Cancer Res"},{"issue":"2","key":"1112_CR50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199\u2013209.","journal-title":"Blood"},{"issue":"7","key":"1112_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s12094-019-02231-7","volume":"22","author":"KV Argyropoulos","year":"2020","unstructured":"Argyropoulos KV, et al. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides. Clin Transl Oncol. 2020;22(7):1059\u201366.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"1112_CR52","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380\u201396.","journal-title":"J Clin Invest"},{"issue":"5","key":"1112_CR53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1189\/jlb.5HI0214-074R","volume":"96","author":"H Janols","year":"2014","unstructured":"Janols H, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol. 2014;96(5):685\u201393.","journal-title":"J Leukoc Biol"},{"issue":"4","key":"1112_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69(4):1553\u201360.","journal-title":"Cancer Res"},{"issue":"6","key":"1112_CR55","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","volume":"184","author":"MF Denny","year":"2010","unstructured":"Denny MF, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284\u201397.","journal-title":"J Immunol"},{"key":"1112_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745326","volume":"12","author":"SL Tucker","year":"2021","unstructured":"Tucker SL, Sarr D, Rada B. Granulocytic myeloid-derived suppressor cells in cystic fibrosis. Front Immunol. 2021;12: 745326.","journal-title":"Front Immunol"},{"key":"1112_CR57","doi-asserted-by":"publisher","first-page":"8567320","DOI":"10.1155\/2020\/8567320","volume":"2020","author":"C Chen","year":"2020","unstructured":"Chen C, et al. Targeting myeloid-derived suppressor cells is a novel strategy for anti-psoriasis therapy. Mediators Inflamm. 2020;2020:8567320.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"1112_CR58","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3892\/mmr.2016.5685","volume":"14","author":"D Ilkovitch","year":"2016","unstructured":"Ilkovitch D, Ferris LK. Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. Mol Med Rep. 2016;14(4):3935\u201340.","journal-title":"Mol Med Rep"},{"issue":"11","key":"1112_CR59","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","volume":"35","author":"G Ferrer","year":"2021","unstructured":"Ferrer G, et al. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021;35(11):3163\u201375.","journal-title":"Leukemia"},{"issue":"6","key":"1112_CR60","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1182\/blood.V61.6.1105.1105","volume":"61","author":"SO Pember","year":"1983","unstructured":"Pember SO, et al. Density heterogeneity of neutrophilic polymorphonuclear leukocytes: gradient fractionation and relationship to chemotactic stimulation. Blood. 1983;61(6):1105\u201315.","journal-title":"Blood"},{"issue":"2","key":"1112_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031524","volume":"7","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender ZG, et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE. 2012;7(2): e31524.","journal-title":"PLoS ONE"},{"issue":"12","key":"1112_CR62","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"JR Chan","year":"2006","unstructured":"Chan JR, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577\u201387.","journal-title":"J Exp Med"},{"issue":"1","key":"1112_CR63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/ijms19010179","volume":"19","author":"A Chiricozzi","year":"2018","unstructured":"Chiricozzi A, et al. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19(1):179.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1112_CR64","doi-asserted-by":"publisher","first-page":"138","DOI":"10.36849\/JDD.2020.4645","volume":"19","author":"L Green","year":"2020","unstructured":"Green L, et al. Clinical and molecular effects of interleukin-17 pathway blockade in psoriasis. J Drugs Dermatol. 2020;19(2):138\u201343.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1112_CR65","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjd.12705","volume":"170","author":"AG Hendriks","year":"2014","unstructured":"Hendriks AG, et al. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. Br J Dermatol. 2014;170(3):571\u201380.","journal-title":"Br J Dermatol"},{"issue":"20","key":"1112_CR66","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"M Tokuyama","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1112_CR67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.immuni.2020.07.003","volume":"53","author":"U Cytlak","year":"2020","unstructured":"Cytlak U, et al. Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans. Immunity. 2020;53(2):353-370.e8.","journal-title":"Immunity"},{"issue":"10","key":"1112_CR68","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/jid.2010.165","volume":"130","author":"J Fuentes-Duculan","year":"2010","unstructured":"Fuentes-Duculan J, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010;130(10):2412\u201322.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1112_CR69","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jaci.2021.04.021","volume":"148","author":"J Kim","year":"2021","unstructured":"Kim J, et al. Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. J Allergy Clin Immunol. 2021;148(5):1281\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1112_CR70","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.immuni.2014.08.006","volume":"41","author":"N McGovern","year":"2014","unstructured":"McGovern N, et al. Human dermal CD14+ cells are a transient population of monocyte-derived macrophages. Immunity. 2014;41(3):465\u201377.","journal-title":"Immunity"},{"key":"1112_CR71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202345","author":"S Nakamizo","year":"2021","unstructured":"Nakamizo S, et al. Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20202345.","journal-title":"J Exp Med"},{"key":"1112_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6500","author":"G Reynolds","year":"2021","unstructured":"Reynolds G, et al. Developmental cell programs are co-opted in inflammatory skin disease. Science. 2021. https:\/\/doi.org\/10.1126\/science.aba6500.","journal-title":"Science"},{"issue":"2","key":"1112_CR73","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/all.15486","volume":"78","author":"B Zhang","year":"2023","unstructured":"Zhang B, et al. Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. Allergy. 2023;78(2):439\u201353.","journal-title":"Allergy"},{"key":"1112_CR74","doi-asserted-by":"publisher","first-page":"1038744","DOI":"10.3389\/fimmu.2022.1038744","volume":"13","author":"D Xia","year":"2022","unstructured":"Xia D, et al. Applications of single-cell RNA sequencing in atopic dermatitis and psoriasis. Front Immunol. 2022;13:1038744.","journal-title":"Front Immunol"},{"issue":"6","key":"1112_CR75","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.jaci.2020.11.028","volume":"147","author":"J Liu","year":"2021","unstructured":"Liu J, et al. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer. J Allergy Clin Immunol. 2021;147(6):2370\u201380.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01112-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01112-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01112-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T13:26:07Z","timestamp":1711459567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01112-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01112-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3042896\/v1","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Other than that mentioned above, Julia Tittes reports consulting fees from Lilly, speaker honoraria from Lilly and Novartis, all outside the submitted work, as well as travel support from Almirall, AbbVie and Bristol-Myers Squibb through institution. Julia M. Ressler received speaker honoraria from Bristol-Myers Squibb, Roche, Amgen and Novartis and travel support by Sanofi, Roche and Bristol-Myers Squibb through institution. All other authors declare no conflicts of interest (COI). The corresponding author, Julia Tittes, has changed her affiliation after the completion of the manuscript. Her new affiliation is the Institute for Clinical Pathology and Molecular Pathology at the University Clinic St.P\u00f6lten-Lilienfeld (Karl Landsteiner University).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved in accordance with the Helsinki Declaration of 1964 and its later amendments by the ethics committee of the Medical University of Vienna (ECS 1642\/2017) on the 25th of September 2017 and followed national law and ethical principles in research. It required voluntary participation of patients and healthy controls with written informed consent. Additionally, all patients gave written informed consent to the release of clinical images captured.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}